Additional file 3 of Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T

Supplementary Material 3. Figure S3 Histological and immunohistochemical analysis of tumor tissue in mice. (A): HE stains of tumor tissues reveals dense, irregular tumor cells with a high nucleus-to-cytoplasm ratio in the MOCK-T group, indicative of active proliferation. Immunohistochemical analysis shows elevated Ki-67 and BCL-2 expression in the MOCK-T group, supporting its high proliferative activity and anti-apoptotic properties. In contrast, the gp350-CAR-T group displays extensive necrosis and apoptosis, with loosely arranged cells and elevated Bax expression, indicating enhanced apoptosis. Additionally, increased CD3-positive T cell infiltration and reduced gp350 levels in the gp350-CAR-T group confirm its targeted anti-tumor activity. (B): Quantification of the immunohistochemical staining for Bax, BCL-2, Ki-67, CD3, and gp350. The MOCK-T group exhibits significantly higher Ki-67 and BCL-2 levels, associated with greater proliferative activity and anti-apoptotic properties, while the gp350-CAR-T group shows markedly increased Bax expression, indicating enhanced apoptosis. CD3-positive T cell infiltration and reduced gp350 expression in the gp350-CAR-T group further confirm the specific anti-tumor effect of gp350-CAR-T cells.